Results from two Flexion Therapeutics, Inc. (Nasdaq: FLXN) sponsored pivotal clinical trials showed that its lead drug candidate Zilretta (also ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE